ClinicalTrials.gg
RecruitingNCT06596187Updated Oct 15, 2024

Differential Assessment of Hypertonia

An interventional study of Continuous passive motion device (CPM) of ankle - fast and Continuous passive motion device (CPM) of ankle - slow in SCI - Spinal Cord Injury and PD - Parkinson's Disease, sponsored by Chang Gung University. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Chang Gung University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Spinal Cord Injuries with a site in Taiwan — 9 open to participants now, 9 under way, none of them phase 3. Spinal Cord Injuries · Taiwan.

Planned enrollment
8th of 22
45 · median 20
Started
2024
with 4 others
No phase
17 of 31
7 open now
Registered
25th of 31
by date
Lead sponsor
5 of 31
Chang Gung University

Among the 31 studies in Spinal Cord Injuries with a site in Taiwan, this one is the 8th largest by planned enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2024, is one of 17 with no phase, and was the 25th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

9 of the 31 studies in Spinal Cord Injuries with a site in Taiwan are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 20 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Spinal Cord Injuries with a site in Taiwan, or all of them as a file.
02

Study summary

Spasticity and rigidity are common symptoms of central nervous system injuries, such as spinal cord injury and Parkinson's disease, and result in distinct patterns of increased resistance during passive joint movements. Spasticity is characterized by a velocity-dependent increase in stretch reflexes, accompanied by exaggerated tendon responses, while rigidity is marked by consistent resistance throughout the range of motion, traditionally considered independent of stretch velocity. However, recent studies suggest that rigidity may also be influenced by stretch velocity. This study aims to investigate muscle tone by examining spasticity, rigidity, and normal muscle function through neural and biomechanical changes. Standard clinical tools, such as the Modified Ashworth Scale and Unified Parkinson's Disease Rating Scale, along with additional assessments like the Myoton and Post-Activation Depression (PAD), will be employed.

Read the detailed description

Spasticity and rigidity are common symptoms resulting from central nervous system injuries (e.g., spinal cord injury and Parkinson's disease). During passive joint movement, spasticity and rigidity manifest as two distinct patterns of increased resistance. Spasticity is a type of hypertonia characterized by a stretch reflex that increases with speed, accompanied by exaggerated tendon reflexes. Rigidity, on the other hand, is another form of hypertonia, where resistance increases during passive movement and remains consistent throughout the range of motion.

The degree of rigidity is traditionally considered independent of stretch velocity, which is one of the key differences from spasticity. However, recent studies have found that rigidity may also increase with stretch velocity. Despite attempts to distinguish different types of hypertonia based on stretch velocity, these efforts have largely been unsuccessful. Many factors influence muscle tone, which can be broadly categorized into changes in neural and biomechanical properties. The Modified Ashworth Scale and the Unified Parkinson's Disease Rating Scale are the most commonly used clinical tools for assessing spasticity and rigidity. Additionally, devices such as the Myoton or laboratory parameters like Post-Activation Depression (PAD) are also used for assessment.

03

Conditions studied

  • SCI - Spinal Cord Injury
  • PD - Parkinson's Disease

Keywords

  • Spasticity
  • Post activation depression
  • Passive motion device (CPM)
  • Rigidity
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Health subjects:

Exclusion Criteria:

  1. Musculoskeletal injuries on legs.
  2. Osteoporosis.

SCI subjects:

Inclusion Criteria 1. Participants with chronic spinal cord injury, with injury duration greater than one year.

Exclusion Criteria

  1. Current musculoskeletal or joint injuries in the lower limbs.
  2. History of central or peripheral neuromuscular diseases.
  3. Presence of a pacemaker.
  4. Current use of antispastic or antidepressant medications.
  5. Current venous thromboembolism or osteoporosis.
  6. Impairment of the soleus H-reflex arc.

PD subjects:

Inclusion Criteria:

  • Clinical diagnosis of Parkinson disease.

Exclusion Criteria:

  1. Musculoskeletal injuries on legs
  2. Osteoporosis.
  3. Any peripheral or central nervous system injury or disease patients.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Healthy Participants

    To establish the relationship between changes in foot pressure during ankle joint movement, muscle tone, and Post-Activation Depression (PAD).

    Procedure: Continuous passive motion device (CPM) of ankle - fast · Procedure: Continuous passive motion device (CPM) of ankle - slow

  • Experimental
    PD Patients

    To establish the relationship between changes in foot pressure during ankle joint movement, muscle tone, and Post-Activation Depression (PAD).

    Procedure: Continuous passive motion device (CPM) of ankle - fast · Procedure: Continuous passive motion device (CPM) of ankle - slow

  • Experimental
    SCI Patients

    To establish the relationship between changes in foot pressure during ankle joint movement, muscle tone, and Post-Activation Depression (PAD).

    Procedure: Continuous passive motion device (CPM) of ankle - fast · Procedure: Continuous passive motion device (CPM) of ankle - slow

Interventions

  • ProcedureContinuous passive motion device (CPM) of ankle - fast

    Continuous passive motion device (CPM) of ankle at 1HZ(60rpm) for 10 repetitions

    Also known as: fast CPM

  • ProcedureContinuous passive motion device (CPM) of ankle - slow

    Continuous passive motion device (CPM) of ankle 0.25HZ (15rpm) for 10 repetitions

    Also known as: slow CPM

06

What researchers measure

Primary outcomes

  1. H-reflex Amplitude

    The peak-to-peak amplitude of the H-reflex measured in the soleus muscle to assess spinal motor neuron excitability. Unit: Millivolts (mV)

    Time frame: Before CPM, immediately after CPM

  2. M-wave Amplitude

    The peak-to-peak amplitude of the M-wave recorded in the soleus muscle to assess peripheral motor neuron excitability and muscle response. Unit: Millivolts (mV)

    Time frame: Before CPM, immediately after CPM

  3. Level of Post-Activation Depression (PAD) of the H-reflex.

    The H-reflex will be elicited by electrical stimulation of the tibial nerve (or other motor nerves), and PAD will be assessed by measuring the reduction in H-reflex amplitude following a series of repetitive stimuli. The amplitude of the H-reflex after repeated stimulation will be compared to the baseline single stimulus.

    Time frame: Before CPM, immediately after CPM

  4. H/M ratio

    The H/M ratio is calculated by dividing the amplitude of the H-reflex by the amplitude of the M-wave.

    Time frame: Before CPM, immediately after CPM

  5. Muscle Tone (Frequency, Hz)

    This parameter measures the natural oscillation frequency of the muscle in response. It reflects the muscle's state of tension or readiness

    Time frame: Before CPM, immediately after CPM

  6. Elasticity (Dynamic Stiffness, N/m)

    Elasticity, measured in Newtons per meter, reflects the muscle's ability to return to its original shape after being deformed by the impulse

    Time frame: Before CPM, immediately after CPM

  7. Stiffness (Decay, ms)

    This parameter quantifies the rate at which the muscle returns to its initial state after the impulse, indicating the muscle's stiffness.

    Time frame: Before CPM, immediately after CPM

  8. Mechanical Stress (Creep, s) and Relaxation (S)

    These parameters measure the time it takes for muscle tissue to adapt to a sustained force (creep) and the time it takes for the muscle to return to a relaxed state after removing the force (relaxation)

    Time frame: Before CPM, immediately after CPM

  9. Plantar foot pressure distribution and peak pressure

    Foot pressure will be measured using a pressure sensors during ankle movement.

    Time frame: Measured continuously during CPM

Secondary outcomes

  1. M-wave Latency

    The time from the onset of electrical stimulation to the onset of the M-wave response in the soleus muscle, used to assess changes in peripheral nerve conduction velocity. Unit: Milliseconds (ms)

    Time frame: Before CPM, immediately after CPM

Other outcomes

  1. Muscle spasticity levels as assessed by the Modified Ashworth Scale (MAS).

    Muscle spasticity levels will be assessed using the Modified Ashworth Scale (MAS), which evaluates resistance during passive soft-tissue stretching. This measure will be used to evaluate changes in muscle tone before and immediately after the intervention. Unit: MAS score (ordinal scale from 0 to 4, where 0 indicates no increase in muscle tone and 4 indicates rigidity in flexion or extension)

    Time frame: Baseline

  2. Overall the Parkinson's Disease Questionnaire-39 (PDQ-39) Score

    An aggregated score derived from the eight dimension scores, providing a comprehensive measure of the individual's quality of life.

    Time frame: Baseline

  3. Overall the Patient Reported Impact of Spasticity Measure(PRISM) Score

    : An aggregated score derived from all the individual items within the questionnaire, providing a comprehensive measure of the impact of spasticity on the patient's quality of life.

    Time frame: Baseline

  4. Total The Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score

    The sum of scores from all 14 items, providing an overall measure of motor impairment severity.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Aug 2026, 22 months after the start.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 22 months is below that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2024
First posted
Sep 19, 2024
StartActual
Oct 9, 2024
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06596187
Lead sponsor
Chang Gung University
Responsible party
Ya-Ju Chang (Professor, Chang Gung University) — Principal investigator
First posted
Sep 19, 2024
Start date
Oct 9, 2024
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Oct 15, 2024

Study contacts

Ya-Ju Chang, PhD
Contact
yjchang@mail.cgu.edu.tw
+88632118800 ext. 5515

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion